Variety of suitable clients: CDEC reviewed the uncertainty in the volume of people with moderately severe to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some sufferers who will be classified as having mild or average condition could possibly have a serious blee